Melatonin Treatment in Children with Developmental Disabilities

Schwichtenberg, A. J.; Malow, Beth A.

doi:10.1016/j.jsmc.2015.02.008

Cited by 54 publications

(42 citation statements)

References 39 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the dose, duration, and elements of sleep affected by melatonin vary considerably across studies, the cumulative findings provide support for melatonin treatment (Doyen et al, 2011; Guénolé & Baleyte, 2011; Rossignol & Frye, 2011; Schwichtenberg & Malow, 2015). The most consistent finding across studies of individuals with ASD and associated genetic conditions is decreases in sleep onset latency.…”

Section: Syndrome/condition Specific Sleep Problemsmentioning

confidence: 86%

Sleep in Neurodevelopmental Disorders

Esbensen

Schwichtenberg

2016

International Review of Research in Developmental Disabilities

Self Cite

View full text Add to dashboard Cite

Individuals with intellectual and developmental disabilities (IDD) experience sleep problems at higher rates than the general population. Although individuals with IDD are a heterogeneous group, several sleep problems cluster within genetic syndromes or disorders. This review summarizes the prevalence of sleep problems experienced by individuals with Angelman syndrome, Cornelia de Lange syndrome, Cri du Chat syndrome, Down syndrome, fragile X syndrome, Prader-Willi syndrome, Smith-Magenis syndrome, Williams syndrome, autism spectrum disorder, and idiopathic IDD. Factors associated with sleep problems and the evidence for sleep treatments are reviewed for each neurodevelopmental disorder. Sleep research advancements in neurodevelopmental disorders are reviewed, including the need for consistency in defining and measuring sleep problems, considerations for research design and reporting of results, and considerations when evaluating sleep treatments.

show abstract

Section: Syndrome/condition Specific Sleep Problemsmentioning

confidence: 86%

Sleep in Neurodevelopmental Disorders

Esbensen

Schwichtenberg

2016

International Review of Research in Developmental Disabilities

Self Cite

View full text Add to dashboard Cite

show abstract

“…Its therapeutic applications are numerous, from pediatric [49,50,51] to geriatric diseases [52,53,54]; this includes cancer [55,56], sleep disturbances [57,58] and neurodegenerative diseases [59,60]. …”

Section: Why Melatonin?mentioning

confidence: 99%

Melatonin as a Potential Agent in the Treatment of Sarcopenia

Coto‐Montes

Boga

Tan

et al. 2016

IJMS

View full text Add to dashboard Cite

Considering the increased speed at which the world population is aging, sarcopenia could become an epidemic in this century. This condition currently has no means of prevention or treatment. Melatonin is a highly effective and ubiquitously acting antioxidant and free radical scavenger that is normally produced in all organisms. This molecule has been implicated in a huge number of biological processes, from anticonvulsant properties in children to protective effects on the lung in chronic obstructive pulmonary disease. In this review, we summarize the data which suggest that melatonin may be beneficial in attenuating, reducing or preventing each of the symptoms that characterize sarcopenia. The findings are not limited to sarcopenia, but also apply to osteoporosis-related sarcopenia and to age-related neuromuscular junction dysfunction. Since melatonin has a high safety profile and is drastically reduced in advanced age, its potential utility in the treatment of sarcopenic patients and related dysfunctions should be considered.

show abstract

“…In adults, taking melatonin in low doses of 0.1-0.3 mg 2 h prior to bedtime is thought to be effective in raising the plasma melatonin to normal levels. The doses which may be effective in children are unclear [3,4,[15][16][17][18][19].…”

Section: Melatonin and Melatonin Agonistsmentioning

confidence: 99%

Pharmacotherapy of Insomnia in Children

Pelayo

Huseni

2016

Curr Sleep Medicine Rep

View full text Add to dashboard Cite

Insomnia is defined as the inability to fall asleep and/or the inability to maintain sleep to the point that it has a negative impact on time awake. Insomnia in adults may lead to daytime fatigue and sleepiness but in children, the lack of quality sleep may lead to daytime behavioral problems such as hyperactivity and academic difficulty. The pharmacological treatment of insomnia in children is a challenging problem for clinicians since there is paucity of Food and Drug Administration (FDA) approved. Parents often seek medical attention for their children when their own or other members of the family's sleep schedule has been disrupted. The clinician has to take into account the entire family when evaluating a child and making therapeutic recommendations. When evaluating a child with insomnia, it is not only important to take a thorough history of the child's sleep schedule but it also involves getting a detailed evaluation of the other family member's sleep history. The pharmacological management of insomnia is dependent on the child's age. The primary healthcare physician may have limited training in pediatric sleep disorders. Although the mainstay treatment for insomnia in children is behavioral therapy, in this chapter, we will provide a review of the medications that may be used as an adjunct treatment for pediatric insomnia.

show abstract

Melatonin Treatment in Children with Developmental Disabilities

Cited by 54 publications

References 39 publications

Sleep in Neurodevelopmental Disorders

Sleep in Neurodevelopmental Disorders

Melatonin as a Potential Agent in the Treatment of Sarcopenia

Pharmacotherapy of Insomnia in Children

Contact Info

Product

Resources

About